Recurrent Childhood Acute Lymphoblastic Leukemia Clinical Trial
Official title:
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVE:
I. To determine the objective response rate to MLN8237 (alisertib) in children with relapsed
or refractory solid tumors and leukemias, administered once daily for 7 days every 21 days.
SECONDARY OBJECTIVES:
I. To further define and describe the toxicities of MLN8237 administered on this schedule.
II. To further characterize the pharmacokinetics of MLN8237 in children with refractory
cancer.
III. To evaluate aurora A kinase expression using immunohistochemistry in solid tumors and
leukemic blasts from tissue obtained at diagnosis and, if available, at relapse.
IV. To explore the relationship between polymorphic variations in the
UDP-glucuronosyltransferase gene UGT1A1 and exposure to MLN8237, and to assess 2 common
polymorphic variants in the aurora A kinase gene, Phe31Ile and Val57Ile.
OUTLINE: This is a multicenter study. Patients are stratified according to type of tumor
(measurable neuroblastoma vs neuroblastoma with metaiodobenzylguanidine [MIBG]-positive
lesions vs osteosarcoma vs Ewing sarcoma/primitive neuroectodermal tumor [PNET] vs
rhabdosarcoma vs non-rhabdomyosarcoma [RMS] soft tissue sarcoma vs hepatoblastoma vs
malignant germ cell tumor vs Wilms tumor vs acute myeloid leukemia [AML] vs acute
lymphoblastic leukemia [ALL] vs rhabdoid tumors).
ARM I (NEUROBLASTOMA- MEASURABLE): Patients receive alisertib orally (PO) once daily (QD) on
days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease
progression or unacceptable toxicity.
ARM II (NEUROBLASTOMA-MIBG EVALUABLE): Patients receive alisertib PO QD on days 1-7.
Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or
unacceptable toxicity.
ARM III (RHABDOMYOSARCOMA): Patients receive alisertib PO QD on days 1-7. Treatment repeats
every 21 days for up to 35 courses in the absence of disease progression or unacceptable
toxicity.
ARM IV (OSTEOSARCOMA): Patients receive alisertib PO QD on days 1-7. Treatment repeats every
21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
ARM V (EWING SARCOMA/ PERIPHERAL PNET): Patients receive alisertib PO QD on days 1-7.
Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or
unacceptable toxicity.
ARM VI (NON-RMS SOFT TISSUE SARCOMA): Patients receive alisertib PO QD on days 1-7. Treatment
repeats every 21 days for up to 35 courses in the absence of disease progression or
unacceptable toxicity.
ARM VII (HEPATOBLASTOMA): Patients receive alisertib PO QD on days 1-7. Treatment repeats
every 21 days for up to 35 courses in the absence of disease progression or unacceptable
toxicity.
ARM VIII (MALIGNANT GERM CELL TUMOR): Patients receive alisertib PO QD on days 1-7. Treatment
repeats every 21 days for up to 35 courses in the absence of disease progression or
unacceptable toxicity.
ARM IX (WILMS TUMOR): Patients receive alisertib PO QD on days 1-7. Treatment repeats every
21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
ARM X (ACUTE LYMPHOBLASTIC LEUKEMIA): Patients receive alisertib PO QD on days 1-7. Treatment
repeats every 21 days for up to 35 courses in the absence of disease progression or
unacceptable toxicity.
ARM XI (ACUTE MYELOGENOUS LEUKEMIA): Patients receive alisertib PO QD on days 1-7. Treatment
repeats every 21 days for up to 35 courses in the absence of disease progression or
unacceptable toxicity.
ARM XII (RHABDOID MALIGNANCY): Patients receive alisertib PO QD on days 1-7. Treatment
repeats every 21 days for up to 35 courses in the absence of disease progression or
unacceptable toxicity.
Plasma samples are collected from all patients at baseline and periodically during course 1
for pharmacokinetic and other studies.
After completion of study therapy, patients are followed up for 5 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00897325 -
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
|
||
Completed |
NCT01403415 -
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Completed |
NCT00093821 -
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
|
Phase 1 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00031655 -
Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission
|
Phase 2 | |
Completed |
NCT00003528 -
Raltitrexed in Treating Children With Refractory Acute Leukemia
|
Phase 1 | |
Completed |
NCT00022737 -
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
|
Phase 3 | |
Recruiting |
NCT03241940 -
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
Completed |
NCT01817075 -
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
|
Phase 3 | |
Completed |
NCT02847130 -
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
|
||
Completed |
NCT00105001 -
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
|
Phase 2 | |
Terminated |
NCT00101205 -
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT00898404 -
Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate
|
N/A | |
Terminated |
NCT00058461 -
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
|
Phase 2 |